Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX)

Gotham Asset Management LLC reduced its stake in Gain Therapeutics, Inc. (NASDAQ:GANX) by 52.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 158,155 shares of the company’s stock after selling 176,437 shares during the period. Gotham Asset Management LLC owned approximately 0.60% of Gain Therapeutics worth $342,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Sprott Inc. acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $30,000. Benedict Financial Advisors Inc. acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $35,000. Bridgeway Capital Management LLC acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $65,000. Northern Trust Corp boosted its holdings in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after acquiring an additional 39,642 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $198,000. 11.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GANX has been the topic of several recent analyst reports. Scotiabank initiated coverage on Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price on the stock. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a report on Friday, March 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Stock Down 2.6%

NASDAQ:GANX opened at $1.91 on Wednesday. The stock’s fifty day moving average price is $1.93 and its two-hundred day moving average price is $2.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The company has a market cap of $56.46 million, a price-to-earnings ratio of -1.74 and a beta of 0.17. Gain Therapeutics, Inc. has a 52-week low of $0.89 and a 52-week high of $3.19.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). On average, analysts anticipate that Gain Therapeutics, Inc. will post -1 EPS for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.